Lab group sues FDA over fi­nal rule reg­u­lat­ing lab­o­ra­to­ry-de­vel­oped tests

Last year
Pharma
FDA+

Bris­tol My­er­s' CAR-T ther­a­py Breyanzi adds new ap­proval in man­tle cell lym­phoma

Last year
Pharma
Cell/Gene Tx

FDA to be­gin re­struc­tur­ing its in­spec­tion of­fice in Oc­to­ber

Last year
FDA+
Manufacturing

UK won’t or­der Grail’s can­cer test for 1M peo­ple this year, a set­back for di­vesti­ture plans

Last year
Diagnostics

Al­mac’s 2023 rev­enue bump; France to in­vest in eas­ing green­house gas im­pact

Last year
Manufacturing

Doc­tors who en­dorse drugs on so­cial me­dia are of­ten com­pen­sat­ed, JA­MA study finds

Last year
Pharma
FDA+

The bio­phar­ma news we’re pay­ing at­ten­tion to at AS­CO

Last year
R&D

No­var­tis ends de­vel­op­ment of KRAS drug, cit­ing 'in­creas­ing op­tions avail­able'

Last year
R&D
Pharma

Flush with cash, No­vo Nordisk Foun­da­tion now plans to rein­vest some GLP-1 prof­its in­to re­gen­er­a­tive med­i­cines

Last year
R&D
Cell/Gene Tx

Com­pu­gen, Nx­era dis­close mile­stone pay­ments; In­smed aims for $650M of­fer­ing

Last year
News Briefing

Ex­clu­sive: Plen­ful nabs $17M to au­to­mate phar­ma­cy op­er­a­tions

Last year
Deals
Health Tech

Cin­Rx rais­es $73M to cre­ate more biotechs, fur­ther sup­port obe­si­ty drug de­vel­op­ment

Last year
Financing
Startups

Bridge­Bio touts ad­di­tion­al AT­TR-CM drug da­ta in new analy­ses of Phase 3 tri­al

Last year
R&D

Im­muno­vant post­pones tri­al read­outs for its late-stage FcRn drug as it pri­or­i­tizes an­oth­er

Last year
R&D

In­sur­ance up­start Clover Health launch­es new busi­ness sell­ing its tech, bor­row­ing from Os­car play­book

Last year
Health Tech

Up­dat­ed: Dol­lar Gen­er­al shuts down mo­bile clin­ic pro­gram

Last year
Health Tech

FDA ap­proves Tris Phar­ma's non-stim­u­lant pe­di­atric AD­HD liq­uid med­ica­tion

Last year
Pharma
FDA+

Lil­ly's Retev­mo lands new ac­cel­er­at­ed ap­proval for pe­di­atric can­cers

Last year
Pharma
FDA+

Com­pa­ny de­vel­op­ing video games for AD­HD an­nounces sale

Last year
Deals
Pharma

Ori Biotech, Cy­ti­va sep­a­rate­ly un­veil tech to ac­cel­er­ate cell ther­a­py pro­duc­tion

Last year
Cell/Gene Tx
Manufacturing

BioN­Tech to in­crease mR­NA vac­cine foot­print in Africa with $145M in­vest­ment

Last year
Pharma

Am­gen nabs FDA ap­proval for first Soliris in­ter­change­able biosim­i­lar

Last year
Pharma
FDA+

Ar­row­head plots next steps for RNAi ther­a­pies af­ter mid-stage win in mixed hy­per­lipi­demia

Last year
R&D

Bio­haven’s au­toim­mune drug dis­ap­points in­vestors in study of healthy vol­un­teers 

Last year
R&D
First page Previous page 150151152153154155156 Next page Last page
A service from the Financial Times